http://www.aktietorget.sehttp://www.aktietorget.sehttp://www.aktietorget.se/img/Aktietorget_logo.gifAktietorgets RSS feed. De 20 senaste nyheternaCopyright (c) 2008 Aktietorget ABAktietorget ABwebmaster@aktietorget.sepressmeddelanden@aktietorget.seen-UShttp://www.aktietorget.se/NewsItem.aspx?ID=65712N.B. The English text is an unofficial translation and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of G5 Entertainment AB (publ.), reg. no 556680-823878, (the “Company”) are hereby summoned to attend at the annual general meeting held at 4.30 pm (CET) on Wednesday, 19 June 2013, at Hotell Kung Carl, Birger Jarlsgatan 21, Stockholm, Sweden. The entire notice is available at the Company’s website (http://g5e.se/corporate) and at Akitetorget’s website (http://aktietorget.se)SE0001824004G5 Entertainment5/22/2013 8:05:25 AMNotification Shareholders who wish to participate at the annual general meeting must: - be recorded in the share register maintained by Euroclear Sweden AB on Thursday, 13 June 2013; - no later than 4 pm (CET) Monday, 17 June 2013, given notice of their participation and potential assistants to G5 Entertainment AB, Box 5339, 102 47 Stockholm, by facsimile +46 8 545 075 49 or by e-mail mailto:agm@g5e.se stating full name, personal identification number or registration number, address, day-time phone number and when applicable information regarding any representative, proxy or assistant. Shareholders whose shares are nominee-registered must, in order to have the right to attend the annual general meeting, request to be temporarily registered in the share register kept by Euroclear Sweden AB. The shareholder must instruct their nominee thereof in ample time prior to Thursday, 13 June 2013, by which date such registration must be executed. Shareholders represented by proxy shall issue a written and dated power of attorney signed by the shareholder. A power of attorney issued by a legal entity shall have a registration certificate attached, or if such certificate do not exist, equivalent documents. A power of attorney form for shareholders who wish to participate by proxy are available on the Company’s website (http://g5e.se/corporate). The power of attorney shall be presented in original at the annual shareholders meeting. Personal data obtained from the share register kept by Euroclear Sweden AB, the notification of participation at the annual general meeting, and information regarding representatives, proxies and assistants will be used for registration, preparation of the voting register for the annual general meeting and, when applicable, for the minutes from the annual general meeting. Agenda 1. Opening of the annual general meeting 2. Preparation and approval of the voting register 3. Election of chairman of the general meeting 4. Presentation and approval of the agenda 5. Election of two persons to together with the chairman to verify the minutes 6. Determination of whether the meeting has been duly convened 7. Presentation by the CEO 8. Presentation of the annual report and auditor’s report, as well as consolidated financial statements and auditor's report for the group. 9. Resolution regarding: a. Adoption of the income statement and balance sheet, as well as the consolidated income statement and consolidated balance sheet; b. Treatment of the Company's profits or losses in accordance with the adopted balance sheet; and c. Discharge from liability for the directors and the CEO 10. Determination of the number of directors and alternate directors, as well as the number of auditors and alternate auditors 11. Determination of remuneration for the board of directors and auditors 12. Election of the board of directors and potential alternate directors 13. Election of auditors and potential alternate auditors 14. Resolution regarding authorizing the board of directors to resolve to issue shares 15. Resolution regarding incentive plan for the management 16. Resolution regarding the establishment of a nominating committee and how the nominating committee shall be appointed 17. Closure of the meeting Accounting documents and audit reports (item 8) and the board of directors’ complete proposal under item 14 and 15 will be available at the Company’s office at Grev Turegatan 14, Stockholm from, and including, Wednesday 29 May 2013 and is mailed upon request in connection therewith to shareholders’ stating their address. The documents will also be available at the Company’s website http://g5e.se/corporate and be presented at the general meeting. Item 3 – Election of chairman of the general meeting Mats Dahlberg is proposed as chairman of the general meeting. Item 9b - Resolution regarding the treatment of the Company's profits or losses in accordance with the adopted balance sheet The board of directors proposes that retained earnings plus profit for the year is carried forward. Item 10 - Determination of the number of directors and auditors The board of directors is proposed, until the closure of the next annual general meeting, to comprise of five (5) directors. It is proposed that one registered auditing firm shall be appointed. Item 11 - Determination of remuneration for the board of directors and auditors The remuneration for the upcoming term is proposed to be SEK 240 000 for the chairman of the board of directors and SEK 150 000 to each of the other directors appointed by the annual general meeting not being employed by the Company. As previously, it is proposed that remuneration to the auditor shall be paid according to approved invoices. Item 12 - Election of a board of directors Jeffrey Rose (reelection), Pär Sundberg (reelection), Vladislav Suglobov (reelection, also CEO) and Petter Nylander (new election) are proposed as directors. Petter Nylander (new election) is proposed as chairman of the board of directors. Recruitment of a fifth director is in progress and a proposed director will be presented at the general meeting. Item 13 – Election of auditors The registered auditor firm Mazars Set Revisionsbyrå AB is proposed as auditor. Item 14 - Resolution regarding authorizing the board of directors to resolve to issue shares The board of directors proposes that the annual general meeting until the next annual general meeting authorizes the board of directors, with or without deviation from the shareholders’ preferential right, on one or more occasions, to resolve on issuance of a maximum of 880 000 shares, meaning an increase of the share capital of a maximum of SEK 88 000, corresponding to a dilution of about 10 per cent of the share capital and voting right. The purpose of the authorization is to enable acquisitions and fundraisings. It shall be possible to pay by kind, set-of or otherwise be subject to conditions. Deviation from the shareholders’ preferential right shall be allowed to be made in a situation where a directed issue, because of time, business or similar considerations is more beneficial for the Company. The issue price shall at all times be as close to market value as possible with the discount required to achieve full subscription. A valid resolution requires that shareholders at the meeting representing at least 2/3 of the numbers of shares and votes represented votes in favor of the proposal (Chapter 13 of the Companies Act). Item 15 - Resolution regarding incentive plan for the management At the extraordinary general meeting held on 31 October 2012 the Company adopted a share-based incentive plan for the period 2012-2014 with an annual allocation (the “Plan”). The board of directors’ proposal of issuance of warrants and 2013 allocation In accordance with the general guidelines set out for the Plan at the extraordinary general meeting on 31 October 2012, the board of directors proposes that the 2013 annual general meeting resolves to issue warrants according to the following principal terms (the “2013 Allocation”): • The maximum number of issued warrants shall be 176 000. • Management and senior executives shall, with deviation from the shareholders’ preferential rights, have the right to subscribe for the warrants. The subscription to the warrants shall be made from and including 4 July 2013 to and including 4 August 2013. Subscription shall be made on a separate subscription list. • The price for the warrants shall correspond with the warrants market value determined by a generally accepted valuation model (the Black-Scholes model). The measurement period for the calculation of the price with the Black-Scholes model shall be from and including 20 June 2013 to and including 3 July 2013. • Subscription for shares, by exercising the warrants, shall be made from and including 4 August 2016 to and including 2 November 2016. • Each warrant shall entitle to subscription for one (1) share in the Company at an issue price of 250 per cent of the volume weighted average quoted closing price (but not less than the quotation value of SEK 0.1) according to Aktietorget’s list of rates for the Company’s share of the period from and including 20 June 2013 to and including 3 July 2013. Days without quotation shall not be included in the calculation. • Upon full exercise of the warrants, up to 176 000 shares (subject to any recalculation), equivalent to about two per cent of the total number of outstanding shares and votes, will be issued. If fully subscribed, the Company’s share capital will increase with SEK 17 600, resulting in a dilution of two per cent. The calculation is based on the number of shares and votes that may be issued divided by the total number of shares and votes after such issuance. • The 2013 Allocation shall include a maximum of 16 persons. The number of warrants that each employee is offered to subscribe for shall vary depending on the employee’s responsibility and position. The CEO and managing director of the group shall be offered a maximum of 20 000 warrants and other management personal are divided into categories which will be offered a maximum of 15 000 warrants and at least 5 000 warrants. The board of directors shall decide on who shall be included in each category, and who shall receive warrants. Directors are not entitled to subscribe for warrants, with the exception of the Company’s CEO. • Issuance of warrants to employees outside Sweden is dependent on tax effects, that no legal impediment exists and that the board of directors determines that such allocation can be made at reasonable administrative and/or financial cost. • In order to be allotted warrants the employee has to sign a special pre-emption agreement with the Company. Pre-emption shall be made at the market value if a third party makes an offer for all shares in the Company and in case the warrants shall be transferred to a third party. Otherwise, the warrants are freely transferable. • The cost for the 2013 Allocation is estimated to be about SEK 100 000. The 2013 Allocation is not expected to materially impact the Company’s earnings per share. The reason for the deviation from the shareholders’ preferential right is to increase motivation and create involvement in the Company’s development and in the opportunity and risk of the Company by management and senior executives. The proposed warrants plan has been prepared by the Company’s board of directors. The CEO did not participate in the preparation of this proposal. A valid resolution requires that shareholders at the meeting representing at least 9/10 of the numbers of shares and votes represented votes in favor of the proposal (Chapter 16 of the Companies Act). 160 000 warrants were issued within the Plan to 15 employees in 2012 (the 2012 allocation). These warrants entitle the holder to subscribe for shares from and including 15 December 2015 to and including 14 March 2016 and the terms and conditions are mainly conform with the terms and conditions for the above proposed warrants. The board of directors or whom the board of directors authorizes shall be authorized to make such minor adjustments of the resolution that may be required in connection with the registration of the issuance at the Companies Registration Office. Item 17 - Resolution regarding the establishment of a nominating committee and how the nominating committee shall be appointed It is proposed that a nomination committee shall be appointed and that the following principles shall apply to the nomination committee. It is proposed that the nominating committee shall consist of representatives of the five (5) largest shareholders as of 30 September 2013. The representative of the largest shareholder of 30 September 2013 is responsible to convene the nomination committee to their first meeting. The nominating committee shall appoint a chairman of the committee. The nominating committee shall be disclosed no later than six months before the annual general meeting. The nomination committee’s term will run until a new committee is appointed. The Company is responsible for costs associated with the nomination committee´s work. Members of the nomination committee receive no compensation from the Company. The nomination committee’s task shall include evaluating the composition and work of the board of directors and to the annual general meeting present a proposal for: - chairman of the annual general meeting - directors and chairman of the board of directors - fees for the directors not employed by the Company - when applicable appointment of register auditor firm and fee for the auditor, and - potential amendment of the principles for how members of the nomination committee shall be appointed If a member of the nomination committee resigns before the nomination committee’s work is complete and if the nomination committee deems it as necessary, a substitute member shall be appointed by the same shareholder who appointed the resigning member. In addition to what is stated above the Swedish Corporate Governance Code, from time to time in force, shall be applicable to the nomination committee. Stockholm May 2013 The Board of Directors More information about the company can be found at: http://www.g5e.se/corporate For additional information please contact: mailto:investor@g5e.se About G5 Entertainment AB (publ) G5 Entertainment AB is a developer and publisher of high quality downloadable games for iPhone, iPad, Android, Mac, Kindle Fire, and Nook tablets. G5 develops and publishes games that are family-friendly, easy to learn, and targeted at the widest audience of experienced and novice players. G5 owns a number of popular game franchises like Virtual City, Special Enquiry Detail, Supermarket Mania, Stand O’ Food, and Mahjongg Artifacts, and invests in creating new games and bringing established franchises to new gaming platforms. Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65596January - March 2013 - Summary * Consolidated revenue for the period is 27 557 KSEK, up 58% compared to 17 388 KSEK for the same period of 2012. This is in line with the previously communicated forecast of 27 MSEK. * Operating result for the period is 8 805 KSEK, up 53% compared to 5 753 KSEK for the same period of 2012. Earnings per share for the period are 0.97 SEK. This result is in line with the previously communicated forecast. * During the period, the group had positive cash flow of 30 971 KSEK. Cash reserves on March 31st 2013 amounted to 44 336 KSEK. * Current assets of the group as of March 31st 2013 were 81 621 KSEK. Current liabilities: 17 799 KSEK. Working capital (CA-CL): 63 822 KSEK. Current ratio (CA divided by CL): 4.59. The group does not have any long-term liabilities, and has strong liquidity position. * The Board of Directors of G5 Entertainment has decided to apply for a listing of the company's shares on NASDAQ OMX Stockholm in the second half of 2013. A listing on NASDAQ OMX Stockholm will increase opportunities for institutional investors to invest in G5 Entertainment and create better liquidity in the share. It is also a further seal of approval for the company in terms of its operations and information disclosures. G5 Entertainment has appointed Carnegie Investment Bank as its financial advisor and Delphi as legal advisor in connection with the listing process. * Warrant Program 2012, as adopted by the Extraordinary General Meeting held on October 31st 2012, has been fully subscribed by managers and senior executives of G5 Entertainment group. Board members except CEO were not entitled to subscribe. Accordingly, G5 Entertainment AB has issued 160 000 warrants. Each warrant entitles the holder to subscribe to one share in the company at an issue price of 106.48 Kr. The period for the warrants is 3 years and 3 months, and it will be possible to exercise warrants after 3 years. Upon full exercise of the warrants, up to 160 000 shares, which represents about two percent of the total number of outstanding shares, will be issued. * On 30th January 2013, G5 Entertainment AB (G5) has completed a directed share issue of 800 000 shares, corresponding to 10 percent of the number of shares outstanding in the Company before the directed share issue. The directed share issue provided the Company with approximately SEK 37.6 million before deductions for issue expenses. There was a strong interest for the transaction and the directed share issue was oversubscribed. The Company retained Carnegie Investment Bank as placing agent in relation to the directed share issue, which was primarily directed towards institutional investors in the Nordic region. The subscription price was SEK 47 per share, corresponding to a discount of 2.3 percent to the closing price on January 29, 2013. As a result of the directed share issue, the total number of outstanding shares increased from 8 000 000 shares to 8 800 000 shares and the share capital increased from SEK 800 000 to SEK 880 000. The proceeds from the directed share issue will allow G5 to capitalize on a positive outlook of the mobile gaming app market and continue its strong historical growth, by increasing the number of external and internal development projects and focusing more on high-quality free-to-play games. * The Secret Society, hidden object free-to-play game released in November 2012, continued gaining the audience and improving monetization as G5 rolled out the updates for the game. The game increased average daily revenue through the period and became the highest grossing among G5 games. * During Q1, G5 continued releasing games every week. G5 released games for iOS, Google Play, Mac, Kindle Fire and Nook stores. In addition to free-to-play games The Secret Society, Virtual City Playground and Doomsday Preppers, the highlights of the quarter included Abyss: the Wraiths of Eden (iOS, Android, Mac), Spirit Walkers (Android), Where Angels Cry (iOS). * The total number of downloads of G5 games on iOS and Android (not counting update downloads) surpassed 100 million. * This interim report has not been reviewed by company’s auditor. SE0001824004G5 Entertainment5/15/2013 8:11:37 AMImportant Events After the End of The Period * The Secret Society, a hidden object free-to-play game, has received updates much anticipated by players, featuring new content and features, and addressing a number of known issues with the game. As a result, the game went up in Top Grossing ranks worldwide considerably, entering Top 50 Grossing Games in USA on iPad, and becoming the highest grossing game in G5’s portfolio on a continuous basis. * The group has 70 games (each for multiple platforms) in the development pipeline to be published in 2013 and 2014. This number also includes a number of free-to-play games to be released starting in 2013. * In effort to strengthen the management team in the areas of disclosure, reporting, and investor relations in anticipation of the company’s application to list shares on Nasdaq OMX Stockholm later this year, G5 Entertainment AB has appointed Odd Bolin to be Chief Financial Officer. Odd started his assignment on May 2nd 2013, succeeding Sergey Shults, who took the position as VP Finance and continues his employment with G5 in this role. Odd Bolin’s most recent assignment was at Cybercom Group, where he was Managing Director of Sweden, and before that CFO of the group. Before joining Cybercom, Odd Bolin held various positions in the field of Corporate Finance and equity research such as Head of H&Q Technology Research. Odd Bolin was also one of the founders and partners of Ceres Corporate Advisors (2003-2009), an M&A advisory firm, working with listed technology, telecom and defense companies in the Nordic region. Odd Bolin is 49 years old, holds a M.Sc. in Engineering and Applied Physics and a Ph.D. in Plasma Physics at the Royal Institute of Technology in Stockholm, Sweden. The Company G5 Entertainment AB (publ) unites a group of companies: G5 Holdings Limited (Malta), G5 Entertainment, Inc. (USA), G5 Holding RUS LLC (Russia), and G5 Holding UKR LLC (Ukraine), all of which are wholly owned subsidiaries of G5 Entertainment AB (publ). G5 Entertainment AB (publ) is listed on Aktietorget exchange in Stockholm since November 19th 2008. Before that, G5 Entertainment AB was listed on NGM Nordic MTF since 2nd October 2006. G5 Entertainment AB acts as a holding company and provides managerial services to the rest of the group. Further, the parent company develops a number of the company’s games and invoices almost all of the Groups’ external revenue. G5 Entertainment Group is a developer and publisher of high quality downloadable casual games for iPhone, iPad, Android, and Mac. G5 Entertainment started as one of the world’s leading mobile game development studios, developing games based on popular licenses for the largest mobile game publishers during 2001-2008. Since 2009, G5 is developing and publishing downloadable games for iPhone, iPad, Android, and Mac. G5’s portfolio includes popular casual games like Supermarket Mania, Special Enquiry Detail, Virtual City, Stand O’Food, and Mahjongg Artifacts. G5 also develops games based on third party licenses, and publishes games developed by third party developers - in both cases, on certain revenue share terms. G5’s development studio has extensive experience of development for smartphones and tablets. One of the group’s main competitive advantages is its proprietary Talisman™ cross-platform technology, which allows effective development and deployment of games across numerous platforms and devices, including iPhone, iPad, Android, Windows Mobile, Mac OS. Talisman technology, in combination with G5’s established processes for the development, porting, adaptation, and quality assurance of games, allows G5 to deploy high quality games to multiple platforms in reduced time. The creative and development teams at G5 are also capable of producing original intellectual property and best-selling casual and free-to-play games like Supermarket Mania 2, Stand O’Food 3, Virtual City, and Virtual City Playground. Accounting Principles G5 Entertainment AB’s consolidated accounts have been prepared in accordance with International Financial Reporting Standards (IFRS). This report was prepared for the group in accordance with the IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The accounting and calculation principles used in the report for the group are identical to those used in the Annual Report 2011. None of the new and changed standards from IFRS, applicable from 1st of January 2012, has had any effect on the Financial Statements. Capitalized expenditure Capitalized expenditure consists of expenses related to the development of new games. Expenses are capitalized only if the expenses are expected to result in identifiable future financial benefits that are under the control of the group. Depreciation is calculated using the straight-line method during a period of two years after the release of the game. Additional Information Any forward-looking statements in this report are based on the management knowledge of the quantity, release dates, and anticipated sales of games which were already released and which are going to be released by the group in the future. Sales for the yet unreleased games are estimated based on historical sales patterns for released games of similar genre and quality level since 2009, also taking into account current market situation and trends. The accuracy of forecasts for yet unreleased games is affected by: a) game release delays due to 3rd party (Apple, Google, Amazon, etc) reviews and approvals on the way to the market; b) game release delays due to group’s “when it’s done” approach to game development - crucial to create high quality games with “long tail” of sales; c) low prediction accuracy when it comes to forecasting sales of games in new genres or on new platforms, when there is no accumulated statistics from similar previously released games; d) general difficulty with predicting sales of a particular game precisely; e) changes in the development plans because of new business opportunities, like new platform announcements, new API releases, and such other important events requiring immediate action and change of development plans. The Share The number of outstanding shares at the end of the period: 8 800 000 shares. The average number of outstanding shares during the period: 8 266 667 shares. Warrant Program 2012, as adopted by the Extraordinary General Meeting held on October 31st 2012, has been fully subscribed by managers and senior executives of G5 Entertainment group. Accordingly, G5 Entertainment AB has issued 160 000 warrants. Each warrant entitles the holder to subscribe to one share in the company at an issue price of 106.48 Kr. The period for the warrants is 3 years and 3 months, and it will be possible to exercise warrants after 3 years. Upon full exercise of the warrants, up to 160 000 shares, which represents about two percent of the total number of outstanding shares, will be issued. On 30th January 2013, G5 Entertainment AB (G5) has completed a directed share issue of 800 000 shares, corresponding to 10 percent of the number of shares outstanding in the Company before the directed share issue. The directed share issue provided the Company with approximately SEK 37.6 million before deductions for issue expenses. There was a strong interest for the transaction and the directed share issue was oversubscribed. The Company retained Carnegie Investment Bank as placing agent in relation to the directed share issue, which was primarily directed towards institutional investors in the Nordic region. The subscription price was SEK 47 per share, corresponding to a discount of 2.3 percent to the closing price on January 29, 2013. As a result of the directed share issue, the total number of outstanding shares increased from 8 000 000 shares to 8 800 000 shares and the share capital increased from SEK 800 000 to SEK 880 000. The proceeds from the directed share issue will allow G5 to capitalize on a positive outlook of the mobile gaming app market and continue its strong historical growth, by increasing the number of external and internal development projects and focusing more on high-quality free-to-play games. This report is published in Swedish and English. In the event of any difference between the English version and the Swedish original, the Swedish version shall prevail. Reporthttp://www.aktietorget.se/NewsItem.aspx?ID=65497Cherry AB (PLC) Annual General Meeting was held on May 7, 2013 at 3 pm, at the restaurant Blekholmen, Blekholmsterrassen in Stockholm. SE0005191426Cherry5/8/2013 11:42:43 AMBoard For the period until the next Annual General Meeting it was decided to re-elect Morten Klein, Rolf Åkerlind, Anders Holmgren and Martin Wattin and in addition elect Gunnar Lind and Magnus Berglind. It was recorded that Kjell Berglind declined his re-election as Board member. Rolf Åkerlind was elected Chairman of the Board. It was decided that the remuneration to the Board of directors would amount to SEK 1 100 000, of which SEK 350 000 for the Chairman and SEK 150 000 to each of the other directors. It was decided that remuneration to the auditor would be paid on the approved account. It was decided unanimously to grant the directors and the CEO discharge for the operations of the company's affairs during the financial year 2012. It was noted that board members representing their own and others' shares, as well as the CEO, did not participate in the decision. Decision on the guidelines for remuneration to senior executives The Board, in accordance with the proposed, decided it to adopt the guidelines for determining salaries and other compensation for the CEO and other senior executive’s inline which was approved in the AGM 2012. Any variable compensation that may be offered to senior executives based on achievement of predetermined targets can be granted with a maximum 100 percent of base salary. Redemption programme The Annual General Meeting decided upon a transfer to shareholders of SEK 143.4 million (9.6), corresponding to SEK 11.20 per share (0.75) through a redemption programme, of which SEK 1.20 per share corresponds to an ordinary transfer to shareholders and SEK 10.00 per share corresponds to an extraordinary transfer to shareholders. Both A- and B-share will be split (2:1) and 1 of the shares will be called redemption share. 1 The last day of trading Cherry shares including the right to redemption shares is April 23. May 20 is the record date for entitlement to redemption shares. The trading in redemption shares will take place between May 22 and June 5 on AktieTorget (class B-shares) or through Erik Penser Bankaktiebolag (class A-shares). The payment in cash of redemption amount is set to 14 of June. If further information regarding the redemption programme please see Cherry´s webpage (only available in Swedish): http://cherry.se/investor-relations/aktieaegarservice.aspx Authorization of new share issue It was decided unanimously to authorize the Board of Directors to, on one or more occasions prior to the next AGM, decide on the issuance of a maximum of 1 280 000 class B shares against cash payment and / or if decided - non-cash, and thereby derogate from existing shareholders’ preference rights. The price for new issued shares shall be based on current market price of the shares. This authorization serves to, swiftly and efficiently, facilitate acquisitions where payments are made in cash or with shares. Complete minutes from the AGM are presented on the company website in Swedish. http://en.cherry.se/investor-relations/shareholder-meetings-and-minutes.aspx If further information is needed in English please contact CFO and IR responsible, Fredrik Burvall, mailto:Fredrik.Burvall@cherry.se, +46 8-514 969 52, +46 709-279 632. Translation This is a translation of the Swedish original. Stockholm, May 8, 2013 Cherry AB The Board of Directors For further information please contact Emil Sunvisson, CEO Cherry AB (PLC), Telephone +46 8-514 969 50, +46 708 109 735, mailto:emil.sunvisson@cherry.se Cherry in brief Cherry is a Swedish gaming company established in 1963 specialized in online casinos and online slot machines; (EuroSlots.com, EuroLotto.com and CherryCasino.com), through subsidiaries in Malta, and in casinos in restaurants in Sweden. Cherry employs around 700 people and has more than 2 400 shareholders. The Company's B-shares are listed on AktieTorget Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65462SE0001824004G5 Entertainment5/7/2013 8:24:00 AMG5 Entertainment AB (G5) has appointed Odd Bolin to be Chief Financial Officer. Odd started his assignment on May 2, succeeding Sergey Shults, who took the position as VP Finance and continues his employment with G5 in this role. “G5 has previously announced plans to apply for listing on Nasdaq OMX Stockholm in the second half of 2013. The listing will put additional disclosure, reporting, and investor relations requirements on the company, and by adding Odd to our team in CFO capacity we aim to use his practical experience in these fields, and generally strengthen the team”, says Vlad Suglobov, CEO of G5 Entertainment AB. Odd Bolin’s most recent assignment was at Cybercom Group, where he was Managing Director of Sweden, and before that CFO of the group. Before joining Cybercom, Odd Bolin held various positions in the field of Corporate Finance and equity research such as Head of H&Q Technology Research. Odd Bolin was also one of the founders and partners of Ceres Corporate Advisors (2003-2009), an M&A advisory firm, working with listed technology, telecom and defense companies in the Nordic region. Odd Bolin is 49 years old, holds a M.Sc. in Engineering and Applied Physics and a Ph.D. in Plasma Physics at the Royal Institute of Stockholm, Sweden. More information about the company can be found at: http://www.g5e.se/corporate. For additional information please contact: mailto:investor@g5e.se About G5 Entertainment AB (publ) G5 Entertainment AB is a developer and publisher of high quality downloadable games for iPhone, iPad, Android, Mac, Kindle Fire, and Nook tablets. G5 develops and publishes games that are family-friendly, easy to learn, and targeted at the widest audience of experienced and novice players. G5 owns a number of popular game franchises like Virtual City, Special Enquiry Detail, Supermarket Mania, Stand O’ Food, and Mahjongg Artifacts, and invests in creating new games and bringing established franchises to new gaming platforms. Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65457Highlights First quarter – the Automaten sites were sold for MSEK 286 – Online Gaming grew with 35 percent. • Group turnover increased with 14 percent and amounted to MSEK 59.8 (52.3). • EBIT amounted to MSEK -1.3 (1.4). • On the 19th of February Cherry completed the sales of the Automaten sites for MSEK 286. The result for the divested operations amounted to MSEK +26.4. • The Group Cash amounted to MSEK 262.7 (45.3) at the end of the period. • The result after tax amounted to MSEK -2.0 (0.0) equivalent to SEK -0.15 (0.00) per share after dilution. • Earnings per share (including divested operations) amounted to SEK 1.84 (0.55) per share. • Online Gaming grew during the first quarter with 35 percent and deposits within Online Gaming increased with 84 percent. • Restaurant Casino increased the turnover and the market share increased to 59 percent (56) of the active gaming tables. • In January Cherry was awarded a license in the German state of Schleswig-Holstein to provide online casino gaming. • In January Cherry filed a lawsuit at the Oslo City Court against the Norwegian state regarding the injunction issued by the Lottery-og Stiftelsestilsynet, against Cherry AB concerning Eurolotto.com.SE0005191426Cherry5/7/2013 8:00:38 AMEvents after the end of the quarter • The board has to the Annual General Meeting proposed a share redemption program equivalent to SEK 11.20 per share. • Cherry has as the first customer signed an agreement and invested in the new company Yggdrasil Gaming Ltd. Yggdrasil offers an innovative range of number games and in May, the company was awarded a Class 4 license from the LGA in Malta. • After the Norwegian Lotteritillsynet announced that it would not take any further action against Cherry AB, Cherry has decided to revoke the lawsuit against the Norwegian Government regarding EuroLotto.com. Emil Sunvisson, CEO, comments the first quarter Automaten sites -The sale of the Automaten sites for MSEK 286 has had a major effect on the quarter. We are very pleased to have been able to realize the value in the Automaten sites and can conclude that the Automaten sites have been a very good and profitable business for Cherry and Cherry's shareholders. The sale is a new start for Cherry's online business, where future growth will be created from our own platform, where, we ourselves, control customers, products and offers. Cherry got a very strong cash position, even after the proposed extraordinary dividend, which will be used for an even more aggressive marketing strategy and strategic investments to ensure future growth. An example of our new ventures is the investment in the new company Yggdrasil, which has a great growth potential, although the company still is in an early stage and has a lot to prove. Online Gaming- Intensified efforts creating growth from our own platform, We can conclude that EuroSlots has developed positively, contributing to a healthy growth during the first quarter. The business is increasing rapidly, and a number of new initiatives will be rolled out during the year, including the re-launch of CherryCasino.com and the launch of regional adapted sites. I interpret Lotteritillsynet’s notification that it will not take further action against Cherry as a victory for us and for the Norwegian players looking for an alternative to Norsk Tipping. We will continue to offer EuroLotto to our customers in Europe, Norway included.   Restaurant Casino – Solid performance The first quarter was characterized by a somewhat lower activity in nightclubs, which has negatively affected Cherry. At the same time the acquired entities deliver results as expected. We are actively working to find additional revenues to increase the value created in our operations. For further information please see the full Interim Report 1, 2013. http://en.cherry.se/investor-relations/financial-reports.aspx Translation This is a translation of the Swedish original. Stockholm, May 7, 2013 Emil Sunvisson CEO Cherry AB (PLC) Telephone +46 8-514 969 50, +46 708 109 735, mailto:emil.sunvisson@cherry.se Reporthttp://www.aktietorget.se/NewsItem.aspx?ID=65455Yggdrasil Gaming Ltd has been awarded a class 4 license in Malta by the LGA (Lotteries and Gaming Authority). At the same time Yggdrasil announces its latest innovation, a portfolio of 3D Video Keno games for the online lottery sector.SE0005191426Cherry5/6/2013 5:18:29 PMFor more information, please visit http://www.yggdrasil.com. Emil Sunvisson, CEO Cherry, comments: "The process of getting the license has been smother and faster than expected. With many innovative and unique features and cutting edge 3D graphics, Yggdrasil has really reinvented the Keno game." Stockholm, May 6, 2013 For further information, please contact: Emil Sunvisson, CEO Cherry AB (publ), Telephone +46 8-514 969 50, mailto:emil.sunvisson@cherry.se Yggdrasil in brief Yggdrasil is a new gaming company based in Malta, which develops lottery games for PC, mobile and tablets. Yggdrasil holds an Class 4 license in Malta, and sells its products to various gaming operators. Yggdrasil was founded by Fredrik Elmqvist, former CEO of Net Entertainment Malta. The company employs about 20 people with game studios and game design. www.yggdrasil.com Cherry in brief Cherry is a Swedish gaming company established in 1963 specialized in online casinos and online slot machines; (http://EuroSlots.com, http://EuroLotto.com and http://CherryCasino.com), through subsidiaries in Malta, and in casinos in restaurants in Sweden. Cherry employs around 700 people and has more than 2 400 shareholders. The Company's B-shares are listed on AktieTorget. Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65447At Enzymaticas Annual General Meeting today 6 May 2013, Christian Westin Jansson was elected new Chairman of the Board of Directors and Anders Jungbeck was elected new Board member. The meeting further resolved, inter alia, to implement an incentive program to employees and external Board members who work actively for the Company, and to authorize the Board to issue new shares. SE0003943620Enzymatica5/6/2013 2:20:31 PMThe AGM voted in favour of adopting the income statements and balance sheets for the group and the parent company, and resolved that the funds available at the general meeting should be carried forward and that thus no dividend should be paid for the financial year 2012. The AGM discharged the Board members and the CEO from liability, reelected the ordinary Board members Fredrik Lindberg and Jörgen Rexö and elected Christian Westin Jansson as new Chairman of the Board and Anders Jungbeck as new Board member. No fees will be paid to the Board members. Furthermore, the AGM authorized the Board to resolve on the issue of no more than 2,000,000 new shares, with or without a deviation from the shareholders’ preferential right, for the purpose of enabling the raise of capital to finance the Company’s continuous expansion and for the purpose enabling company acquisitions or acquisition of all or parts of business entities. Last the AGM resolved, in accordance with the Board’s proposal, to implement a long term incentive program in the form of an option program comprising employees and external active Board members of Enzymatica. The new Option Program 2013/2017 shall include a maximum of 850,000 options. For more information, please contact: Michael Edelborg Christensen, CEO Telephone: +46 (0)76-814 41 66 mailto:michael.christensen@enzymatica.se About Enzymatica AB (publ) Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and registration of medical devices based on patented enzyme technology. Enzymatica utilizes a cold-adapted trypsin derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica has two registered medical device products, PeriZyme chewing gum CE, against oral cavity diseases and ColdZyme Mouth Spray CE against common cold, the latter recently launched in pharmacies throughout the country. Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65438AddBIO AB, a subsidiary of Accelerator Nordic AB, has developed Zolidd®, a proprietary add-on for bone implants that enhances the bone holding power by local administration of bisphosphonate, a drug that increases local bone density. A randomized clinical trial shows that Zolidd improves the function of orthopedic external fixation pins.SE0000486607Accelerator5/6/2013 9:22:23 AMExternal fixation with threaded pins is an easy and practical method for (minimally invasive) fracture fixation. It is mainly used for temporary fixation, because of problems with loosening and pin-tract infection, especially in spongeous (porous) bone. This problem can be largely overcome by the use of a hydroxyapatite (HA) coating. HA enables bone formation directly on the pin surface, which reduces loosening, but creates new problems such as difficult and painful removal. In the present study, implants with bisphosphonate were compared to implants coated with HA, as well as plain stainless steel implants. “The study shows that local bisphosphonate improves the fixation in spongeous bone to the same degree that HA does. However, removal was as easy as with uncoated pins”, says Professor Per Aspenberg, Linköping University Hospital, co-author of the study and co-founder of AddBIO. ”This is an important study. Zolidd has now been shown to outperform presently used devices in both orthopedic and dental indications. This is very encouraging when we take the next steps in commercializing Zolidd”, says Ulf Sewerin, CEO of AddBIO AB. Zolidd is the first application from a platform technology designed for local administration of drugs from medical implants, developed by Professor Per Aspenberg, Linköping University, and Professor Pentti Tengvall, Gothenburg University. A nanometer-thin protein layer is attached to the implant surface and a bisphosphonate drug is embedded therein. When placed in the bone, the drug is released, with the effect of locally increasing bone density and strength. In the present study, a Zolidd prototype was used. Twenty patients underwent correction of knee joint angles (tibial osteotomy with hemicallotasis): The bone was cut off below the knee, fixed with external fixation in the desired angle, and allowed to heal. Each patient received two fixation pins in the spongeous bone very close to the knee joint and two in the hard shaft of the bone, one of each prepared with Zolidd. Torques were measured at placement and at removal after three months, and compared to each other and to historic data. No loosening, no pin-track infections, and no increased pain was reported with Zolidd-coated pins. The study was conducted at Hässleholm hospital, Sweden, by Sören Toksvig-Larsen, Hässleholm hospital and LundUniversity, and Per Aspenberg, Linköping University, Sweden. It has now been published online in Acta Orthopaedica http://informahealthcare.com/doi/abs/10.3109/17453674.2013.797315 For additional information, contact Maria Wrethag, CEO Accelerator Nordic AB, +46 76 119 1983. Accelerator Nordic AB is a group of Life Science companies focused on Imaging Software and Medical Nanotechnology. Accelerator’s subsidiaries have exposure towards large growth markets such as oncology, orthopedics, and diagnostics. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information please visit, http://www.acceleratorab.se. Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65343SE0002829226Transferator4/26/2013 8:51:11 AMTransferator AB, a Swedish investment company, today announces that its subsidiary Mr Green & Co AB (“MRGco”) has acquired additional shares in Green Gaming Group Plc (”GGG”) and now holds 51.48% of votes and capital in GGG. The transaction means that GGG is a subsidiary of Mr Green & Co AB. GGG is a Maltese company that owns 100% of the operating company Mr Green Ltd operating the successful internet casino MrGreen.com. Purchase price for the additional shares in GGG is 243.6 Million SEK which has been financed by Mr Green & Co AB entirely by long term loans. Mr Green & Co AB’s book value on its investment in GGG will after the transaction amount to 365.6 Million SEK. During Q1 2013, Green Gaming Group (GGG) has continued the positive progress seen during 2012, with a revenue growth of 60% achieving €12.8 million (2012: €8.0m). This growth has been achieved through a combination of improved market share in core countries and expansion into new territories. Earnings Before Interest, Tax, Depreciation & Amortisation (EBITDA) also improved considerable to €2.8 million (2012: Loss of €0.5 m). The Board of Directors at Transferator AB has proposed to its shareholders at the coming AGM on the 2nd of May to demerge the Mr Green & Co AB group by a dividend to the shareholders on the terms 1:2; meaning two existing shares in Transferator AB will receive one share in Mr Green & Co AB. Record date for participating in the dividend will be decided by the Board of Directors after the AGM has been held. The Board of Directors at Mr Green & Co AB has also expressed their intent to apply for listing of the shares in the company if a decision to progress with the dividend is made. "It is very positive that Mr Green & Co AB is now the largest shareholder in Green Gaming Group Plc, and it becomes consolidating subsidiary in the group. GGG is currently experiencing strong business momentum with high revenue growth combined with good profitability”, says CEO Jakob Johansson in a comment to today’s announcement. For further information, please contact Jakob Johansson, CEO in Transferator AB + 46 735 ‐ 060707 or mailto:jakob.johansson@transferator.com. Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65290SE0003080241Mineral Invest4/24/2013 12:11:25 PMAccording to the decision taken during the extra general meeting on March 22, 2013, the Board of Directors of Mineral Invest has per today decided to issue 1 100 000 000 (1,1 billion) shares to Alluvia Mining Ltd. After the share issue Alluvia Mining’s ownership in Mineral Invest International MII AB corresponds to approximately 53%. The completion of the acquisition signifies that Gold Crown LLC becomes a wholly owned subsidiary of Mineral Invest International AB and simultaneously Alluvia Mining take full ownership of Ghana Gold AB. For more information please contact Andreas Hammerich, CEO phone: +46 73 640 5588, e-post: mailto:andreas.hammerich@mineralinvest.com Charlie Eldh, CFO phone: +46 76 853 8787, e-post: mailto:charlie.eldh@mineralinvest.com About Mineral Invest: Mineral Invest is an international gold company focused on traditional hard rock mining and gold exploration. The Company owns Gold Crown LLC in British Colombia Canada, which holds the Greenwood Property and comprises three high-grade gold and copper mineral deposits. In addition the Company holds two mineral properties in Africa: one 1 442 km large exploration and exploitation concession in the Kilo-Moto Gold Belt in the North East of the Democratic Republic of Congo; the other license area is in the south of Ethiopia near the town of Moyale and comprises a 90km large exploration area. The Company Head Quarter is located in Stockholm, Sweden and the Company's shares are traded on AktieTorget under the ticker MII. For more information please visit http://www.mineralinvest.com Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65280First quarter 2013 in brief * Net sales SEK 579 million (525) * Operating profit SEK 21 million (18) * Profit after financial items SEK 20 million (19) * Equity ratio 55 % (59) * Earnings per share after tax SEK 0.91 (0.87)SE0000772956AQ Group4/24/2013 9:02:03 AMSignificant events during and after the end of the period Net sales rose to 579 MSEK, an increase of 54 MSEK compared with the previous year. Sales excluding acquisitions dropped by 6 % as a result of a reduction in demand. Operating profit and profit after financial items have risen compared with the first quarter last year. Profit per share after tax has risen by 5 %. A 15-MSEK-investment programme in machines and automation equipment is being carried out at AQ Holmbergs Suzhou Co. Ltd in China in order to meet increased volumes during autumn 2013. The office in Denmark, with one employee, was closed in April as a result of low profitability. The wire harnessing business at the Lithuanian AQ Wiring Systems UAB has been developed into a complete company with its own responsibility for sales and purchasing and has also changed its business system. AQ Trafo AB in Sweden is being restructured in order to solely work with market and technology. AQ Magnit AD in Bulgaria, which already manufactured inductive components for Europe, now has total responsibility for sales and purchasing. These changes have led to all operating companies within the group having complete responsibility for their balance sheets and profit and loss accounts. At several companies within the group, we have initiated programmes for management development in order to attain the optimal development of the companies. In 2013 we also started a project aimed at reducing capital tied up in stock. As part of our cost-saving measures at the Swedish companies, staffing levels have been adjusted by approximately 35 employees. AQ Retor’s business in Färgelanda is being wound up and production is being moved to AQ Holmbergs AB in Anderstorp. The lease for AQ Wiring Systems AB’s premises in Töcksfors has been terminated prematurely, which involves an annual saving of approximately 4 MSEK. Information of parent company The parent company, AQ Group AB, focuses primarily on leadership and development of the Group. Company sales are, as in previous years, almost exclusively of sale of management services to subsidiaries. Purchases from the subsidiaries do not exist to any appreciable extent. The drawing up of the interim report The interim report has been prepared in accordance with the Swedish Annual Accounts Act as well as IFRS, applying IAS 34, Interim Financial Reporting, which contains general requirements for the design, structure and minimum information requirements in the interim report. The accounting and valuation principles applied are the same as used in the latest annual report for 2012. The report has not been audited. Significant estimates and evaluations for accounting purposes The Board has in preparing the interim report found no record that would be especially exposed from a risk point of view and thus induce significant adjustments to future periods. Future prospects The board of directors is currently of the opinion that the full year 2013 will be somewhat better than 2012. The Group strives for continued profitable growth within its business areas. The growth will be achieved both organically and through acquisitions. AQ in brief AQ is a leading supplier to demanding industrial customers and is listed on AktieTorget. The Group operates in two business segments Component which produce transformers, cabling, mechanical parts, stamped sheet metal and plastic injection molding and Systems which produces systems, automation and power solutions and assemble complete machines in close cooperation with customers. Reporthttp://www.aktietorget.se/NewsItem.aspx?ID=65260Malmö, 23 April 2013 – Mobile Loyalty plc, the mobile advertising company traded on AktieTorget, Stockholm (ticker: MOBI SDB) (the ”Group”), today announced that it has entered into an agreement with Riksmedia AB with the objective to launch Sweden’s largest mobile advertising network in 2013. In addition, Riksmedia will shortly launch its own news app based on Mobile Loyalty’s solution, integrating news and advertising from Riksmedia’s partners. SE0004296325Mobile Loyalty4/23/2013 8:10:10 AMBy utilizing Mobile Loyalty’s advertising solution for printed media, “ADONnews”, Riksmedia’s partners will in an effortless and cost efficient way be able to set up their own local mobile news apps with its unique adservice for their own local and regional offers, as well as national offers via Riksmedia. Riksmedia’s partners include 108 newspapers that together reach 3 million contacts each week. Riksmedia is the most recent of several media companies that have selected Mobile Loyalty’s service as its mobile platform and advertising solution for its publications. Mobile Loyalty’s solution makes it possible for these companies to quickly launch a mobile service that generates incremental advertising revenues and business opportunities while leveraging existing assets such as advertisers, advertising networks, and sales teams. Nicklas Gerhardsson, Mobile Loyalty CEO commented, “Riksmedia with its national network and reach is a very strong contribution to our customer base. By combining its national advertiser base with its local presence, Riksmedia has created a great launching pad for fully exploring and capitalizing on Mobile Loyalty’s unique advertising service and thus reach its goal of becoming Sweden’s largest mobile advertising network. Theo Blanco, Riksmedia CEO commented, “Having followed Mobile Loyalty and their development for a long period of time, they are the ideal partner for this initiative by Riksmedia. No other provider offers an equally powerful and flexible solution that leverages the unique characteristics of mobiles and hence making it possible to offer advertising solutions with quick ROI for the advertiser.” For additional information, please contact: Nicklas Gerhardsson, CEO Mobile Loyalty +46 70 7633712 mailto:ng@mobileloyalty.com Fredrik Lamotte, Managing Director ADONnews +46 704 66 38 35 mailto:fredrik.lamotte@mobileloyalty.com Theo Blanco, CEO Riksmedia +46 70 6873909 mailto:theo.blanco@riksmedia.se About Mobile Loyalty plc Mobile Loyalty is a Nordic-based provider of advertising solutions for media companies within the fastest growing marketing segment, mobile. We offer proven market leading mobile advertising services for media companies, based upon a revenue sharing model, creating the next generation mobile advertising solutions that allow advertisers and media groups to cost effectively capture the opportunities that arise from the changes in technology and consumer behaviour. Mobile Loyalty is listed on AktieTorget, Stockholm (ticker: MOBI SDB). Follow us at Mynewsdesk: http://www.mynewsdesk.com/uk/pressroom/mobile-loyalty Follow us at AktieTorget: http://www.aktietorget.se/Instrument.aspx?InstrumentID=SE0004296325 Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65232Uppsala, April 19, 2013. Senzime AB (publ) has received its largest order to date from the company's distributor Applikon Biotechnology. The order includes 25 of Senzime’s instruments SENZ-100, which are used to improve the production process of pharmaceuticals. In a first step, the instruments will be marketed in the U.S., UK, Netherlands and Sweden.SE0002478776Senzime4/19/2013 8:47:03 AMThis is the largest order to date from our distributor and represents a major step towards a broader commercialization of our instrument, SENZ-100. As our instruments are being installed at the end customers, Senzime’s sales of disposable sensors and other consumables will increase. Over time, this will result in increased revenues and higher margins, "says Lena Söderström, CEO of Senzime. Applikon Biotechnology is a world leader in the development and sales of advanced bioreactors. The company has its own sales and service organizations in the U.S., UK and China and distributors in over 20 countries. "Applikon Biotechnology focuses on new and innovative technologies in bioprocesses which fit Senzime’s glucose monitoring (sugar measurement) perfect. This is the first technique that provides reliable measurement and control of glucose concentration in the bioreactor, in order to improve the production process of biopharmaceuticals. Glucose is the first analysis we launch, but we are also working towards applying Senzime's technique for measuring other substances, "says Erik Kakes, International Sales & Marketing Director at Applikon Biotechnology. For further information, please contact: Lena Söderström, CEO of Senzime AB Tel: +46-708-16 39 12, e-mail: mailto:lena.soderstrom@senzime.com About Senzime Senzime develops and sells analytical instruments and related disposable products that enable automated, continuous monitoring of vital substances including glucose (sugar), in biological fluids. Many modern medicines are produced in living cells that are nourished in a glucose solution. In order to ensure maximum productivity in manufacturing, glucose levels should be measured continuously. SENZ-100 is an analytical instrument that performs this task. Senzime's market leading partner, Applikon, has started the global launch of SENZ-100. Continuous glucose monitoring can also be used by healthcare providers, to improve outcomes of complex surgical procedures and dialysis care. For these purposes, the company develops the instrument SENZ-200. The company's share is listed on Aktietorget since 2008. http://www.senzime.com Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65163Cherry's Maltese subsidiary PlayCherry Ltd has as the first operator signed an agreement with Yggdrasil Gaming Ltd regarding delivery of 19 different games. Cherry has also, through its subsidiary Cherry Malta Ltd, signed an agreement on financing of Yggdrasil, and is thereby majority owner of Yggdrasil Gaming Ltd.SE0005191426Cherry4/15/2013 9:00:06 AMYggdrasil Gaming is a new gaming company founded by industry veteran Fredrik Elmqvist. With its concept of "NUMB3RS L0V3RS" Yggdrasil offers a wide range of lottery games, including action-packed 3DKeno, scratch cards for both stray players and high rollers. The games are available both on PC, mobile and tablet devices, and offers support for 11 European languages and multiple currencies. Yggdrasil will provide its portfolio of games to gaming operators with a focus on Europe. Yggdrasil has applied for a Class 4 license from the LGA in Malta. The financial investment is expected to have a neutral impact on Cherry's results for the full year 2013, while sales are expected to increase. Emil Sunvisson, CEO Cherry, comments: "We are very impressed with the product portfolio Yggdrasil in a short time has developed, which will strengthen Cherry's online offering. Yggdrasil will continue to operate as an independent company by the founder Fredrik Elmqvist. As a financial investor we hope that this investment will generate good returns for our shareholders." Please note that this is a translation for information purposes only – in case of any discrepancies between this version and the Swedish, the Swedish version shall prevail. Stockholm, April 15, 2013 For further information, please contact: Emil Sunvisson, CEO Cherry AB (publ), Telephone +46 8-514 969 50, mailto:emil.sunvisson@cherry.se Yggdrasil in brief Yggdrasil is a new gaming company based in Malta, which develops lottery games for PC, mobile and tablets. Yggdrasil has applied for a Class 4 license in Malta, and sells its products to various gaming operators. Yggdrasil was founded by Fredrik Elmqvist, former CEO of Net Entertainment Malta. The company employs about 20 people with game studios and game design. http://www.yggdrasil.com Cherry in brief Cherry is a Swedish gaming company established in 1963 specialized in online casinos and online slot machines; (EuroSlots.com ,EuroLotto.com and CherryCasino.com), through subsidiaries in Malta and casinos in restaurants in Sweden. Cherry employs around 700 people and has more than 2 000 shareholders. The Company's B-shares are listed on AktieTorget. Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65117Enzymatica is planning to change its listing and has decided to start the process for listing the company on NASDAQ OMX Stockholm. The listing on the Stockholm Stock Exchange is central to Enzymatica’s international expansion. At the annual general meeting on 6 May, the election of two new members of the Board of Directors will be proposed, to ensure that the company complies with the independence requirements for listed companies on the Stockholm Stock Exchange.SE0003943620Enzymatica4/10/2013 10:48:05 AMAt the Board meeting held on 10 April, the Board resolved to start the process for listing on NASDAQ OMX Stockholm’s small cap list. The Board anticipates that the listing will take place during the first half of 2014. The listing is expected to lead to increased interest among institutional investors and to create conditions for greater liquidity in the shares. A major factor in Enzymatica’s decision to switch from the Aktietorget Equity Market to the Stockholm Stock Exchange is the company’s capital requirements for future international expansion. Enzymatica has signed a number of agreements with leading pharmacy chains in Sweden for the sale of its registered medical devices. Currently, the ColdZyme® Mouth Spray cold treatment is on sale at around half of the country’s pharmacies through Kronans Droghandel and Apotek Hjärtat. Negotiations are under way with additional pharmacy chains, both for the sale of the company’s products in Sweden and, as the next stage, in the Nordic Region. Enzymatica then intends to begin expanding internationally. ”The listing on NASDAQ OMX Stockholm will be a stamp of quality for the company. We have been working tirelessly to build a solid platform for operation as regards market launches, IP (intellectual property rights) and research. It is quite natural that we want to do the same thing for our shares, and apply for a listing on the Stockholm Stock Exchange”, says Michael Edelborg Christensen, CEO of Enzymatica. “The listing will also increase awareness of our brand and company, and this will be vital for future expansion”. In preparation for the listing, Enzymatica has adapted its accounting to the IFRS Standards. Work has also begun to meet the requirements of the Swedish Code of Corporate Governance: and this should be complete during the latter part of 2013. In addition, Enzymatica has implemented changes in the Board of Directors to meet the requirements for independent directors, for example, through the proposals to be submitted to the annual general meeting on 6 May for the election of Christian W Jansson as Chairman of the Board and Anders Jungbeck as a member of the Board. Enzymatica has retained Remium as financial advisors to manage the listing process. Remium is an independent leading investment bank in the capital market for small and medium-sized companies offering a range of services including stockbroking, asset management, share analysis, corporate finance and corporate services. ”We are delighted that Enzymatica has chosen us as financial advisors for their listing on NASDAQ OMX, and we have a great deal of confidence in the company and its products, with ColdZyme at the forefront”, says Remium’s CEO, Mattias Malmström. For more infomration on Enzymatica, please contact: Michael Edelborg Christensen, CEO, Enzymatica AB (publ), + 46 (0)768-14 41 66, mailto:michael.christensen@enzymatica.se About Enzymatica AB (publ) Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and registration of medical devices based on patented enzyme technology. Enzymatica utilizes a cold-adapted trypsin derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica has two registered medical device products, PeriZyme chewing gum CE, against oral cavity diseases and ColdZyme Mouth Spray CE against common cold, the latter recently launched in pharmacies throughout the country. About Enzymatica on the web Enzymatica Newsdesk » http://www.mynewsdesk.com/se/pressroom/enzymatica-ab Enzymatica Website » http://www.enzymatica.com Enzymatica Investor Relations » http://www.aktietorget.se/QuotesInstrument.aspx?Language=1&InstrumentID=SE0003943620 Enzymatica on LinkedIn » http://www.linkedin.com/company/1586902?trk=tyah Enzymatica on Twitter »https://twitter.com/Enzymatica_AB ColdZyme Website » http://www.coldzyme.se/ ColdZyme on facebook » http://www.facebook.com/pages/ColdZyme/162799103808769 Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65095The shareholders of Cherry AB (plc) are invited to the Annual General Meeting on Tuesday 7 of May 2013, starting at 3 pm at restaurant Blekholmen, Blekholmsterassen 15, 111 22 Stockholm.SE0005191426Cherry4/8/2013 5:26:40 PMShareholders who wish to attend the Annual General Meeting (the “AGM”) must • be entered in the register of shareholders held by Euroclear Sweden AB by Tuesday, 30 of April 2013, and • notify Cherry AB (the “Company”) of their intention to participate by Friday, 3 May 2013. Shareholders who wish to attend the AGM must notify the Company in writing at this address: Cherry AB, Blekholmstorget 30, SE-111 64, Stockholm, Sweden. Notification may also be made by telephone +46 8-514 969 52, fax +46 8-514 969 59 or email: mailto:Fredrik.Burvall@cherry.se. When giving notice of attendance, shareholders must state their name, social security number/corporate registration number, address, telephone number and shareholding. Shareholders who are represented by proxy should include such proxy together with the notification to attend the AGM. Those shareholders who wish to be represented by proxy can download a proxy form from the Company’s website http://www.cherry.se. Shareholders with nominee-registered shares must, in order to participate at the AGM temporarily register the shares in his or her own name with Euroclear Sweden AB. Such shareholder must notify its nominee regarding the above-mentioned matter in due time before 30 of April 2013. Full agenda for the Annual Meeting and the re-numeration board proposal will be find in Swedish below. For further information please contact the company´s CFO Fredrik Burvall, +468-514 969 52.   Förslag till dagordning 1. Val av ordförande vid stämman. 2. Upprättande och godkännande av röstlängd. 3. Godkännande av dagordning. 4. Val av en eller två justeringsmän. 5. Prövning av om stämman blivit behörigen sammankallad. 6. Framläggande av årsredovisningen och revisionsberättelsen samt koncernredovisningen och koncernrevisionsberättelsen. I anslutning därtill verkställande direktörens redogörelse för verksamheten. 7. Beslut om: a) fastställelse av resultaträkningen och balansräkningen samt koncernresultaträkningen och koncernbalansräkningen, b) dispositioner beträffande bolagets vinst eller förlust enligt den fastställda balansräkningen, samt c) Ansvarsfrihet för styrelseledamöterna och verkställande direktören. 8. Fastställande av antalet styrelseledamöter. 9. Fastställande av arvoden åt var och en av styrelseledamöterna samt till revisorn. 10. Val av styrelseledamöter. 11. Inrättande av valberedning. 12. Beslut om riktlinjer för ersättning till ledande befattningshavare. 13. Uppdelning av aktier och automatiskt inlösenförfarande innefattande a) beslut om genomförande av uppdelning av aktier, b) beslut om minskning av aktiekapital genom automatisk inlösen av aktier, samt c) beslut om ökning av aktiekapital genom fondemission 14. Beslut om bemyndigande för styrelsen att besluta om nyemission. 15. Övriga ärenden som i behörig ordning hänskjutits till bolagsstämman. 16. Stämmans avslutande. Förslag till beslut Val av ordförande vid stämman (punkten 1) Valberedningen, bestående av Rolf Åkerlind, Pontus Lindwall, Morten Klein och John Wattin, föreslår att advokat Jörgen S. Axelsson utses till ordförande vid årsstämman. Disposition av årets vinst (punkten 7b) Styrelsen föreslår att ingen utdelning lämnas för verksamhetsåret 2012. Styrelsen har föreslagit ett inlösenförfarande motsvarande 11,20 kronor per aktie, varav 1,20 kronor per aktie utgör ordinarie utdelning och 10,00 kronor per aktie utgör extraordinär utdelning, enligt vad som framgår av punkt 13 nedan. Val av styrelseledamöter m.m. (punkterna 8-10) Valberedningen föreslår att styrelsen skall bestå av sex styrelseledamöter valda av bolagsstämman. Till styrelseledamöter för tiden fram till slutet av nästa årsstämma föreslås omval av Anders Holmgren, Morten Klein, Martin Wattin och Rolf Åkerlind samt nyval av Gunnar Lind och Magnus Berglind. Kjell Berggren har meddelat valberedningen att han inte står till förfogande för omval. Valberedningen föreslår att Rolf Åkerlind väljs till styrelsens ordförande. Valberedningen föreslår att arvode till styrelsen för styrelsearbete och utskottsarbete skall utgå med sammanlagt 1 100 000 kronor, varav 350 000 kronor till styrelseordföranden, 150 000 kronor vardera till övriga styrelseledamöter. Arvode till revisorn föreslås utgå enligt godkänd räkning. Valberedningens förslag enligt ovan stöds av aktieägare företrädande cirka 65 procent av rösterna i bolaget. Inrättande av valberedning (punkten 11) Valberedningen föreslår att det inrättas en valberedning enligt följande. Valberedning skall bestå av en representant för envar av de tre till röstetalet största aktieägarna. Därutöver skall styrelsens ordförande vara ledamot i valberedningen. Styrelsens ordförande är sammankallande till valberedningens första sammanträde. Namnen på de tre ägarrepresentanterna och namnen på de aktieägare de företräder skall offentliggöras senast sex månader före årsstämman 2014 och baseras på de kända röstetalen den 30 september 2013. Valberedningens mandatperiod sträcker sig fram till dess att ny valberedning utsetts. Ordförande i valberedningen skall om inte ledamöterna enas om annat vara den ledamot som representerar den till röstetalet största aktieägaren. Om under valberedningens mandatperiod en eller flera av aktieägarna som utsett ledamöter i valberedningen inte längre tillhör de tre till röstetalet största aktieägarna, skall ledamöter utsedda av dessa aktieägare ställa sina platser till förfogande och den eller de aktieägare som tillkommit bland de tre till röstetalet största aktieägarna skall äga rätt att utse sina representanter. Om ej särskilda skäl föreligger skall dock inga förändringar ske i valberedningens sammansättning om endast marginella förändringar i röstetal ägt rum eller förändringen inträffar senare än tre månader före årsstämman. Aktieägare som utsett representant till ledamot i valberedningen äger rätt att entlediga sådan ledamot och utse ny representant till ledamot i valberedningen. Förändringar i valberedningens sammansättning skall offentliggöras så snart sådana skett. Beslut om riktlinjer för ersättning till ledande befattningshavare (punkten 12) Styrelsen föreslår att de riktlinjer för ersättning till ledande befattningshavare som antogs vid årsstämman 2012 i allt väsentligt skall fortsätta att tillämpas. Uppdelning av aktier och automatiskt inlösenförfarande (punkt 13) Styrelsen föreslår att årsstämman fattar beslut om ett automatiskt inlösenförfarande i enlighet med vad som framgår av punkterna 13 a) – 13 c) nedan. Samtliga beslut föreslås vara villkorade av varandra och fattas tillsammans som ett beslut. För giltigt beslut krävs biträde av aktieägare med minst två tredjedelar av såväl de avgivna rösterna som de aktier som är företrädda vid stämman. Beslut om genomförande av uppdelning av aktier (punkt 13 a) Styrelsen föreslår att årsstämman fattar beslut att genomföra en uppdelning av bolagets aktier, s.k. aktiesplit, varvid en befintlig aktie i bolaget, av såväl serie A som serie B, delas i två aktier. En av dessa aktier kommer att vara en s.k. inlösenaktie. Styrelsen föreslår att avstämningsdag för uppdelning av aktie skall vara den 20 maj 2013. Beslut om minskning av aktiekapitalet genom automatisk inlösen av aktier (punkt 13 b) Styrelsen föreslår att årsstämman beslutar att aktiekapitalet skall minskas med 3 520 726,55 kronor genom indragning av 997 600 aktier av serie A och 11 805 042 aktier av serie B för återbetalning till aktieägarna. De aktier som skall dras in utgörs av de aktier som efter genomförd uppdelning av aktie enligt ovan benämns inlösenaktier. Betalning för varje inlösenaktie skall vara 11,20 kronor, vilket överstiger aktiens kvotvärde med cirka 10,93 kronor. Eventuella indragna inlösenaktier av serie A respektive serie B som innehas av bolaget skall dras in utan återbetalning och sådant belopp skall avsättas till fri fond att användas av bolagsstämman. Den totala inlösenlikviden uppgår därmed till högst 143 389 590,40 kronor. Styrelsen föreslår att handel i inlösenaktier av serie B skall ske under tiden från och med den 22 maj 2013 till och med den 5 juni 2013. Styrelsen föreslår vidare att avstämningsdag för indragning av inlösenaktier skall vara den 11 juni 2013. Betalning beräknas ske genom Euroclear Sweden AB:s försorg den 14 juni 2013.   Beslut om ökning av aktiekapitalet genom fondemission (punkt 13 c) För att åstadkomma ett tidseffektivt inlösenförfarande utan krav på tillstånd från Bolagsverket eller allmän domstol, föreslår styrelsen att årsstämman beslutar återställa bolagets aktiekapital till dess ursprungliga belopp genom att öka bolagets aktiekapital med 3 520 726,55 kronor genom fondemission genom överföring från bolagets fria egna kapital till bolagets aktiekapital. Inga nya aktier skall ges ut i samband med ökningen av aktiekapitalet. Bemyndigande för styrelsen att besluta om nyemission (punkten 14) Styrelsen föreslår att årsstämman bemyndigar styrelsen att, vid ett eller flera tillfällen under tiden intill nästa årsstämma, besluta om nyemission av sammanlagt högst 1 280 000 aktier av serie B mot kontant betalning och/eller med bestämmelse om apport samt att därvid kunna avvika från aktieägarnas företrädesrätt. En nyemission av 1 280 000 aktier motsvarar en utspädningseffekt på aktiekapitalet med cirka 10 procent före utspädning. Emissionskursen för de nya aktierna skall baseras på marknadspriset för bolagets aktier. Syftet med bemyndigandet är att på ett tidseffektivt sätt möjliggöra förvärv där betalning sker kontant eller med egna aktier. För giltigt beslut krävs biträde av aktieägare med minst två tredjedelar av såväl de avgivna rösterna som de vid stämman företrädda aktierna. Övrigt Årsredovisning och revisionsberättelse samt styrelsens fullständiga förslag enligt ovan jämte tillhörande redogörelser och yttranden enligt aktiebolagslagen (2005:551) kommer att finnas tillgängliga hos bolaget senast den 16 april 2013 på adress enligt ovan och på bolagets webbplats http://www.cherry.se samt sändas till de aktieägare som anmält sig till stämman eller anmält att de vill ha information via separat utskick. Aktieägare har enligt 7 kap. 32 § aktiebolagslagen (2005:551) rätt att vid bolagsstämman begära upplysningar från styrelsen och verkställande direktören om förhållanden som kan inverka på förhållanden på dagordningen och förhållanden som kan inverka på bolagets ekonomiska situation. Den 8 april 2013 fanns sammanlagt 12 802 642 aktier i bolaget, varav 997 600 aktier av serie A och 11 085 042 aktier av serie B, motsvarande sammanlagt 21 061 042 röster. Please note that this is a translation for information purposes only – in case of any discrepancies between this version and the Swedish, the Swedish version shall prevail. Stockholm, April, 2013 The Board of Directors For further information, please contact: Emil Sunvisson, CEO Cherry AB (publ), Telephone +46 8-514 969 50, mailto:emil.sunvisson@cherry.se Cherry in brief Cherry is a Swedish gaming company established in 1963 specialized in online casinos and online slot machines; (EuroSlots.com ,EuroLotto.com and CherryCasino.com), through subsidiaries in Malta and casinos in restaurants in Sweden. Cherry employs around 700 people and has more than 2 000 shareholders. The Company's B-shares are listed on AktieTorget. Newshttp://www.aktietorget.se/NewsItem.aspx?ID=65082Enzymatica strengthens its Board with competency and experience from the pharmaceutical industry. Anders Jungbeck, vice president of the international pharmaceutical company Actavis, has been proposed as new member of the Board of Enzymatica. Anders Jungbeck has the past 29 years been working in both the Swedish and international pharmaceutical industry in companies as Glaxo, Draco, AstraZeneca and Ratiopharm.SE0003943620Enzymatica4/5/2013 4:30:19 PM- We are very pleased to have Anders Jungbeck to candidate for our Board. By having Anders on the Board we get a good gain in terms of experience from the international pharmaceutical market place, which is especially important in connection with our planned expansion in the Nordic region and Europe, says Michael Edelborg Christensen, CEO of Enzymatica. - It feels really exhilarating to be proposed as a member of Enzymatica. It is a very interesting biotech company with an exciting pipeline of products, says Anders Jungbeck. For more information on Enzymatica, contact: Michael Edelborg Christensen, CEO at Enzymatica AB (publ), 0768-14 41 66, mailto:michael.christensen@enzymatica.se About Enzymatica AB (publ) Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical devices based on patented enzyme technology. Enzymatica utilizes a marine enzyme, a cold-adapted trypsine derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica currently has two registered medical devices, PeriZyme chewing gum against periodontal diseases and ColdZyme Mouth Spray against common cold recently launched in pharmacies throughout the country. About Enzymatica on the web Enzymatica Newsdesk » http://www.mynewsdesk.com/se/pressroom/enzymatica-ab Enzymatica Website » http://www.enzymatica.com Enzymatica Investor Relations » http://www.aktietorget.se/QuotesInstrument.aspx?Language=1&InstrumentID=SE0003943620 Enzymatica on LinkedIn » http://www.linkedin.com/company/1586902?trk=tyah Enzymatica on Twitter »https://twitter.com/Enzymatica_AB ColdZyme Website » http://www.coldzyme.se/ ColdZyme on facebook » http://www.facebook.com/pages/ColdZyme/162799103808769Newshttp://www.aktietorget.se/NewsItem.aspx?ID=64964WntResearch AB (WNT.ST) announces the filing of a Clinical Trial Application (CTA) at the Danish Health and Medicines Authorities (DHMA) for initiation of Phase 1 clinical trial with Foxy-5. The number of patients to be included is unknown since this is a dose escalation study, which primary objective is to evaluate safety and tolerability and to find the recommended dose for Phase 2.SE0003553130WntResearch3/25/2013 10:39:50 AMThe trial is planned to be carried out at the Oncology Unit at the Herlev University Hospital in Denmark in patients with metastatic breast, colorectal or prostate cancers with no or low level of Wnt-5a expression in the primary tumor. The primary objective is to evaluate safety and tolerability and to find the recommended dose for Phase 2. In addition to this, it is the secondary aim to assess preliminary evidence of anti-metastatic tumor activity. The number of cancer patients to be included in the Phase 1 trial is unknown since the dose escalation will continue until Foxy-5 reaches either a dose limiting toxicity or a dose level equivalent to the level that had an anti-metastatic effect in the pre-clinical studies. CEO Nils Brünner comments: "Today we have filed the Clinical trial Application for the first Phase 1-trial with Foxy-5. This is a huge milestone for WntResearch which has taken its lead product, Foxy-5, all the way from discovery to clinical development. Foxy-5 is for the treatment of metastasis – a feared and lethal condition for cancer patients. We look forward to be able to initiate the study." For further information please contact: Nils Brünner, CEO E-mail: Telephone: +45 2614 4708 About Foxy-5 Foxy-5 has a significant market potential within oncology. Foxy-5 represents a first-in-class concept for the treatment of cancer. The study drug targets the metastatic process which is the primary reason for cancer deaths. Foxy-5 will be one of the first antimetastatic products ever to enter clinical trials. Foxy-5 offers a potential paradigm shift to influnce the treatment of many large cancer indications including breast-, colon and prostate cancer. About WntResearch AB WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients. The company has filed a Clinical Trial Application for its lead product, Foxy-5, and is aiming at initiating Phase 1 clinical trials in the second quarter 2013.Newshttp://www.aktietorget.se/NewsItem.aspx?ID=64927Christian W. Jansson, former President and CEO of KappAhl – a leading Swedish clothes retailer – has been proposed as the new Chairman of the Board of Enzymatica. The election of the Board Chairman will be dealt with at the AGM on 6th of May. Christian W. Jansson would replace Åke Larsson, who has not sought reelection.SE0003943620Enzymatica3/21/2013 2:06:20 PM“We are very gratified that Christian W. Jansson has accepted the proposal to be Board Chairman. His experience from the retail trade and publicly traded companies will be valuable now that Enzymatica is commercializing its operations via a broad-based market introduction of ColdZyme®Munspray and other products,” says Michael Edelborg Christensen, CEO at Enzymatica. “Enzymatica is a highly exciting company which is now launching innovative products designed to prevent and treat a number of our most common illnesses, such as colds. I believe that that the company has considerable potential to succeed in building up robust operations both in Sweden and internationally,” notes Christian W. Jansson. Christian W. Jansson is Chairman of the Board of Svensk Handel (Swedish Trade Federation) and Apoteket AB (major Swedish pharmacy chain) and is a member of the boards of Svenskt Näringsliv (Confederation of Swedish Enterprise), Bong AB, KappAhl AB, Europris AS and others. Christian W. Jansson has also been active in the Bonnier Dental Group, which is responsible both for global and European operations. For more information on Enzymatica, contact: Michael Edelborg Christensen, CEO at Enzymatica AB (publ), 0768-14 41 66, michael.christensen@enzymatica.se About Enzymatica AB (publ) Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical devices based on patented enzyme technology. Enzymatica utilizes a marine enzyme, a cold-adapted trypsine derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica currently has two registered medical devices, PeriZyme chewing gum against diseases and ColdZyme CE oral spray for colds recently launched in pharmacies throughout the country. About Enzymatica on the web Enzymatica Newsdesk » http://www.mynewsdesk.com/se/pressroom/enzymatica-ab Enzymatica Website » http://www.enzymatica.com Enzymatica Investor Relations » http://www.aktietorget.se/QuotesInstrument.aspx?Language=1&InstrumentID=SE0003943620 Enzymatica on LinkedIn » http://www.linkedin.com/company/1586902?trk=tyah Enzymatica on Twitter » https://twitter.com/Enzymatica_AB ColdZyme Website » http://www.coldzyme.se/ ColdZyme on facebook » http://www.facebook.com/pages/ColdZyme/162799103808769 Enzymatica AB (publ.), Ideon Science Park, 223 70 Lund Phone: +46 46 286 31 00, http://www.enzymatica.se, http://www.coldzyme.seNewshttp://www.aktietorget.se/NewsItem.aspx?ID=64925Enzymatica has decided to change the date of its Annual General Meeting (AGM) to May 6th, 2013. The company previously announced that the AGM would be held on April 18. However, due to extensive work involved in the adjustment of the annual financial statements and annual report to the IFRS rules and regulations and to be able to offer the proposed new Board members the possibility of participating in the AGM, Enzymatica’s management has decided to change the date to May 6th at 10.00 am. The AGM will be held at Ideon Science Park, Sheelevägen 15 in Lund. For more information about Enzymatica, contact: SE0003943620Enzymatica3/21/2013 1:00:59 PMMichael Edelborg Christensen, VD Enzymatica AB (publ), 0768-14 41 66, mailto:michael.christensen@enzymatica.se About Enzymatica AB (publ) Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical devices based on patented enzyme technology. Enzymatica utilizes a marine enzyme, a cold-adapted trypsine derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica currently has two registered medical devices, PeriZyme chewing gum against diseases and ColdZyme CE oral spray for colds recently launched in pharmacies throughout the country. About Enzymatica on the web Enzymatica Newsdesk » http://www.mynewsdesk.com/se/pressroom/enzymatica-ab Enzymatica Website » http://www.enzymatica.com Enzymatica Investor Relations » http://www.aktietorget.se/QuotesInstrument.aspx?Language=1&InstrumentID=SE0003943620 Enzymatica on LinkedIn » http://www.linkedin.com/company/1586902?trk=tyah Enzymatica on Twitter » https://twitter.com/Enzymatica_AB ColdZyme Website » http://www.coldzyme.se/ ColdZyme on facebook » http://www.facebook.com/pages/ColdZyme/162799103808769 Enzymatica AB (publ.), Ideon Science Park, 223 70 Lund Phone: +46 46 286 31 00, http://www.enzymatica.se, http://www.coldzyme.seNews